Global HealthQ2 FY24

Global Health Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,436.6P/E: 59.6Market Cap: ₹38.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • Strong volume growth driven by higher patient footfalls across all hospital units (Q2 FY ’24 inpatient volumes up 19.4% YoY).
  • Continued bed additions planned: 125–150 beds in Lucknow and ~50 beds in Patna by end of current fiscal year.
  • Expansions at Patna and Lucknow progressing well, with focus on critical care infrastructure.
  • New hospital projects underway: Noida expected to commence operations by FY ’25 end; Medanta Delhi Hospital (DLF JV) progressing.
  • Addition of 250+ doctors in H1 FY ’24 supporting volume and service growth.
  • Higher occupancies sustained with mature cluster occupancy around 65%.
  • Focus on tariff increases in developing hospitals (Patna, Lucknow) to improve ARPOB in medium term.
  • Operating leverage benefits expected as facilities scale, improving margins alongside volume growth.

See what Global Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript does not mention any current or planned fundraising through debt or equity explicitly.
  • The company has a strong net cash positive balance sheet with approximately INR600 crores of net cash.
  • This healthy balance sheet positions Medanta well to fund future expansion plans and growth internally without the need for immediate external fundraising.
  • Medanta's growth and capex plans, such as expansions in Lucknow, Patna, Noida, and the DLF partnership, are expected to be funded through internal accruals and existing cash resources.
  • No explicit mention of fundraising via debt or equity was made during the call or in the provided pages.

See what Global Health management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Medanta plans significant capex over the next three years, estimated at INR 1,000-1,100 crores, primarily for expansions in Lucknow, Patna, Noida, and maintenance.
  • Lucknow capacity to increase from 601 to about 950 beds with related capex.
  • Patna to expand capacity to nearly 650 beds, including around 50 ICU beds due to high demand for critical care.
  • Noida hospital is a 550-bed facility, with 300 beds in the initial phase; capex incurred includes INR 308 million in H1 FY ‘24.
  • Gurgaon expects limited capex mainly for interior fit-outs for ~100 bed additions, plus INR 70-100 crores over next year for medical equipment upgrades.
  • Maintenance capex for mature units likely around INR 60-75 crores annually.
  • Funding is supported by a strong net cash positive balance sheet (~INR 600 crores net cash).
  • Strategic partnerships include the joint venture with DLF and exploration of greenfield and O&M models for expansion in central India and the NCR region.

Track Global Health — get its next earnings analysis in your feed

How does Global Health rank vs peers in Healthcare Services?

Pro feature
ThisGlobal Health
Rev 2Mar 3

How does Global Health rank in Healthcare Services?

Compare Global Health against every Healthcare Services company (Q2 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →